Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.

Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. Am Heart J. 2016 08; 178:176-84.

View in: PubMed

subject areas

Acute Coronary Syndrome
Age Factors
Aged
Cardiovascular Diseases
Double-Blind Method
Female
Hemorrhage
Humans
Lactones
Male
Middle Aged
Myocardial Infarction
Myocardial Revascularization
Patient Readmission
Platelet Aggregation Inhibitors
Proportional Hazards Models
Pyridines
Randomized Controlled Trials as Topic
Recurrence
Stroke
Treatment Outcome

authors with profiles

Robert Harrington